Lextemy (bevacizumab)
Biosimilar
- Region
- 🇪🇺 EU
- Active substance
- bevacizumab
- Company
- Mylan IRE Healthcare Limited
- Status
- Withdrawn
- Therapeutic area
- Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
- CHMP opinion
- Thu 25 Feb 2021
- Designations
- Biosimilar
- Application
- EMEA/H/C/005611
- ATC
- L01XC07
- Official record
- www.ema.europa.eu
Indication
Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Mvasi Authorised · Amgen Europe B.V.
- 🇪🇺 Aybintio Authorised · Samsung Bioepis NL B.V.
- 🇪🇺 Lytenava Authorised · Outlook Therapeutics NL B. V.
- 🇪🇺 Orblid Application withdrawn · Laboratoires Delbert
- 🇪🇺 Abevmy Authorised · Biosimilar Collaborations Ireland Limited
- 🇪🇺 Zirabev Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Avzivi Authorised · FGK Representative Service GmbH
- 🇪🇺 Alymsys Authorised · Mabxience Research SL
- 🇪🇺 Oyavas Authorised · STADA Arzneimittel AG
- 🇪🇺 Vegzelma Authorised · Celltrion Healthcare Hungary Kft.
- 🇪🇺 Avastin Authorised · Roche Registration GmbH
- 🇪🇺 Onbevzi Withdrawn · Samsung Bioepis NL B.V.
Follow Lextemy
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.